Pharmala Biotech Holdings Inc.
MDMA
CNSX
| 02/28/2025 | 11/30/2024 | 08/31/2024 | 05/31/2024 | 02/29/2024 | |
|---|---|---|---|---|---|
| Net Income | -62.65% | -112.64% | 45.98% | -82.98% | -720.60% |
| Total Depreciation and Amortization | -7.14% | 180.00% | 1,066.67% | -97.44% | 0.86% |
| Total Amortization of Deferred Charges | -4.27% | -11.36% | 16.81% | -- | -- |
| Total Other Non-Cash Items | 67.91% | -28.02% | -1.96% | 1,170.63% | -125.79% |
| Change in Net Operating Assets | 233.78% | 68.97% | 16.18% | -243.83% | 179.44% |
| Cash from Operations | -1.73% | -5,889.66% | 98.24% | -108.32% | -855.24% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -4,770.22% | 47.65% | 2.30% | 38.41% | -36.47% |
| Cash from Investing | -4,770.22% | 47.65% | 2.30% | 38.41% | -36.47% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 3,644.47% | -- | -100.00% | -- | -100.00% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | 4.07% | -- | -- |
| Cash from Financing | 3,428.48% | 263.49% | -103.54% | -- | -100.00% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 129.10% | -187.63% | -116.70% | 346.10% | -765.69% |